Effect of Termination on Sublicenses. If this Agreement terminates for any reason, any Sublicensee will, from the effective date of such termination, automatically become a direct licensee of Isis with respect to the rights sublicensed to the Sublicensee by Akcea; so long as (i) such Sublicensee is not in breach of its sublicense agreement, (ii) such Sublicensee agrees in writing to comply with all of the terms of this Agreement to the extent applicable to the rights originally sublicensed to it by Akcea, and (iii) such Sublicensee agrees to pay directly to Isis such Sublicensee’s payments under this Agreement to the extent applicable to the rights sublicensed to it by Akcea. Akcea agrees that it will confirm clause (i) of the foregoing in writing at the request and for the benefit of Isis and if requested, the Sublicensee.
Appears in 3 contracts
Samples: Development, Commercialization and License Agreement, Development, Commercialization and License Agreement (Akcea Therapeutics, Inc.), Development, Commercialization and License Agreement (Akcea Therapeutics, Inc.)
Effect of Termination on Sublicenses. If this Agreement terminates for any reason, then any Sublicensee will, from the effective date of such termination, automatically become a direct licensee of Isis Ionis with respect to the rights sublicensed to the Sublicensee by Akcea; so long as (ia) such Sublicensee is not in breach of its sublicense agreementSublicense, (iib) such Sublicensee agrees in writing to comply with all of the terms of this Agreement to the extent applicable to the rights originally sublicensed to it by Akcea, and (iiic) such Sublicensee agrees to pay directly to Isis Ionis such Sublicensee’s payments under this Agreement to the extent applicable to the rights sublicensed to it by Akcea. Akcea agrees that it will confirm clause (ia) of the foregoing in writing at the request and for the benefit of Isis Ionis and if requested, the Sublicensee.
Appears in 2 contracts
Samples: License Agreement (Ionis Pharmaceuticals Inc), License Agreement (Akcea Therapeutics, Inc.)